Evidence map›Paper›PMID 32847902›Full record

Trial reportBMJ open2020

Smartphone-delivered self-management for first-episode psychosis: the ARIES feasibility randomised controlled trial.

Thomas Steare, Puffin O'Hanlon, Michelle Eskinazi, David Osborn, Brynmor Lloyd-Evans, Rebecca Jones, Helen Rostill, Sarah Amani, Sonia Johnson

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas SteareDivision of Psychiatry, University College London, London, UK.ORCID 0000-0002-3881-2018
Puffin O'HanlonDivision of Psychiatry, University College London, London, UK.
Michelle EskinaziDivision of Psychiatry, University College London, London, UK.
David OsbornDivision of Psychiatry, University College London, London, UK.
Brynmor Lloyd-EvansDivision of Psychiatry, University College London, London, UK.
Rebecca JonesDivision of Psychiatry, University College London, London, UK.
Helen RostillUniversity of Surrey, Guildford, Surrey, UK.
Sarah AmaniEarly Intervention in Psychosis Programme (South of England), Oxford, UK.
Sonia JohnsonDivision of Psychiatry, University College London, London, UK s.johnson@ucl.ac.uk.ORCID 0000-0002-2219-1384

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo test the feasibility and acceptability of a randomised controlled trial (RCT) to evaluate a Smartphone-based self-management tool in Early Intervention in Psychosis (EIP) services.

designA two-arm unblinded feasibility RCT.

settingSix NHS EIP services in England.

participantsAdults using EIP services who own an Android Smartphone. Participants were recruited until the recruitment target was met (n=40).

interventionsParticipants were randomised with a 1:1 allocation to one of two conditions: (1) treatment as usual from EIP services (TAU) or (2) TAU plus access to My Journey 3 on their own Smartphone. My Journey 3 features a range of self-management components including access to digital recovery and relapse prevention plans, medication tracking and symptom monitoring. My Journey 3 use was at the users' discretion and was supported by EIP service clinicians. Participants had access for a median of 38.1 weeks. PRIMARY AND SECONDARY OUTCOME MEASURES: Feasibility outcomes included recruitment, follow-up rates and intervention engagement. Participant data on mental health outcomes were collected from clinical records and from research assessments at baseline, 4 months and 12 months.

results83% and 75% of participants were retained in the trial at the 4-month and 12-month assessments. All treatment group participants had access to My Journey 3 during the trial, but technical difficulties caused delays in ensuring timely access to the intervention. The median number of My Journey 3 uses was 16.5 (IQR 8.5 to 23) and median total minutes spent using My Journey 3 was 26.8 (IQR 18.3 to 57.3). No serious adverse events were reported.

conclusionsRecruitment and retention were feasible. Within a trial context, My Journey 3 could be successfully delivered to adults using EIP services, but with relatively low usage rates. Further evaluation of the intervention in a larger trial may be warranted, but should include attention to implementation.

trial registrationISRCTN10004994.

Indexed as

Psychotic DisordersSelf-ManagementAdultEnglandFeasibility StudiesHumansSmartphoneclinical trialsmental healthschizophrenia & psychotic disorders

Identifiers

PMID32847902
PMCPMC7451533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.